Overview
Metanephrine refers to the inactive metabolites of catecholamines, specifically epinephrine and norepinephrine, formed by the action of catechol O-methyltransferase within chromaffin cells. These metabolites include metanephrine and normetanephrine and are produced continuously, unlike catecholamines, which are released episodically. Because of this constant production, metanephrines are considered more reliable biochemical markers for detecting catecholamine-secreting tumors such as pheochromocytomas and paragangliomas. Measurement of metanephrines in plasma or urine plays a key role in evaluating secondary hypertension, adrenal incidentalomas, and hereditary tumor syndromes, and is regarded as the gold standard initial biochemical test for these conditions.
Symptoms
Its testing itself does not cause symptoms, but it is indicated in patients with clinical features suggestive of excess catecholamine secretion. Common symptoms include episodic or sustained hypertension, severe headaches, palpitations, sweating, tachycardia, pallor, and anxiety. These manifestations often occur in sudden spells and may be associated with haemodynamic instability. In some patients, symptoms may be triggered during stress, anesthesia, or surgical procedures. Persistent or unexplained hypertension, especially in younger individuals, frequently prompts evaluation using metanephrine testing.
Causes
Elevated metanephrine levels are primarily caused by catecholamine-secreting tumors such as pheochromocytomas and paragangliomas. These tumors arise from chromaffin cells and produce excessive catecholamines, which are continuously metabolized into metanephrines within the tumor tissue. Increased levels may also be influenced by severe stress, acute illness, or the use of certain medications that interfere with catecholamine metabolism. Since these are produced independently of catecholamine release episodes, their elevation reflects sustained tumor activity rather than intermittent hormone secretion.
Risk Factors
Risk factors for abnormal metanephrine levels include a personal or family history of pheochromocytoma or paraganglioma, genetic syndromes such as multiple endocrine neoplasia type 2 and von Hippel-Lindau disease, and the presence of adrenal masses discovered incidentally on imaging. Improper patient preparation, such as failure to rest before sampling, dietary influences, stress, and use of interfering drugs, may result in false positive results. Renal impairment can also affect interpretation, particularly for urinary measurements, making plasma-free metanephrines more suitable in such cases.
Prevention
Prevention of diagnostic errors relies on correct patient preparation and appropriate sample collection. Patients should observe overnight fasting, avoid alcohol, caffeine, tobacco, strenuous exercise, and stress prior to testing, and discontinue interfering medications when clinically feasible. Blood samples should be collected with the patient in a fully recumbent position after adequate rest, and plasma should be processed and stored promptly. Proper selection of plasma or urine testing based on clinical context, along with correlation of results with symptoms and imaging studies, ensures accurate diagnosis and timely management of catecholamine-secreting tumors.
